Fan Cao

Ms. Fan Cao

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 October 2025 in Cancers
Verified
Journal Article
Open access
PDF file
QYQian Yu
Qian Yu
FCFan Cao
Fan Cao
PHPeter J Hosein
Peter J Hosein
BHBin Huang
Bin Huang
PPPaulo Pinheiro
Paulo Pinheiro
Aman ChauhanAman Chauhan
Aman Chauhan
Importance: Neuroendocrine tumors (NETs) have traditionally been considered rare (orphan) diseases; however, improvements in diagnostic methods and heightened awareness about NETs may have altered their epidemiologic profile in the U.S. Objective: To evaluate trends in incidence, prevalence, and survival of NETs in the United States from 2000 to 2021 using updated data from the SEER-22 registry. Method: This population-based, retrospective cohort study used the SEER-22 database for incidence, prevalence, and survival analyses. Data included 231,659 patients diagnosed with NETs between 2000 and 2021. Age-adjusted incidence, limited-duration prevalence, 5-year overall survival (OS), and hazard ratios (HRs) for survival by grade, stage, year of diagnosis, race, and primary site were investigated. Results: From 2000 to 2021, NET incidence nearly doubled, from 4.6 to 8.2 per 100,000 persons. The prevalence in 2021 reached 0.064%, with grade 1 tumors showing the steepest increase. Five-year OS was 77.4% overall and highest among localized NETs (82.3%) and grade 1 tumors (80.0%). Multivariable analysis showed improved survival over time (HR for 2015–2021 vs. 2000–2004, 0.92; 95% CI, 0.89–0.95). Black and American Indian/Alaska Native patients had significantly worse outcomes than White patients. Conclusions and Relevance: NETs are no longer orphan diseases based on current U.S. incidence and prevalence trends. With increasing survival and patient numbers, there is an urgent need for expanded multidisciplinary NET care and research efforts focused on survivorship and quality of life.

20 February 2026 in Eurasian Journal of Medicine and Oncology
Verified
Journal Article
Open access
PDF file
FCFan Cao
Fan Cao
MTMichael Tseng
Michael Tseng
JCJiling Chou
Jiling Chou
PKPriyanka Kanth
Priyanka Kanth
Introduction: Gastrointestinal neuroendocrine tumors (GI NETs) represent 1–2% of malignancies arising in the digestive tract, and the incidence has increased in recent years due to greater use of diagnostic tools. However, institution-level patterns in GI NET case counts and survival remain undercharacterized. Objective: This study aims to evaluate demographic and site-specific case count patterns and survival outcomes across a large multi-hospital healthcare system. Methods: We conducted a retrospective cohort study of 1,813 patients diagnosed with GI NETs across MedStar Health from November 2012 to September 2024. Cases were identified using the International Classification of Diseases (ICD) codes. Tumors were categorized as benign, malignant, or mixed coding history based on ICD patterns. Case counts were stratified by sex, race, age, and tumor site. Survival analyses used unadjusted Kaplan–Meier curves and log-rank tests to compare tumor categories and six anatomical sites (appendix, large intestine, pancreas, rectum, small intestine, stomach). Results: GI NET case counts increased over the study period, with higher counts observed among women and individuals aged 51–74 years. Most diagnoses occurred in White (45.8%) and Black (40.7%) patients. Small-intestinal and rectal NETs were the most frequently identified. Survival patterns showed that female sex, White race, younger age, and benign tumors were associated with the most favorable outcomes. Among all anatomical sites, rectal NETs demonstrated the highest long-term survival. Conclusion: This large institutional study highlights meaningful demographic and site-specific variation in GI NET case counts and descriptive survival patterns. These findings underscore the need for future research addressing access-related and sociodemographic contributors to GI NET outcomes.